Bromfenac Sodium b

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Bromfenac Sodium 是一种非甾体类抗炎药 (NSAID)，具有抗炎活性，可能通过抑制环加氧酶 1 和 2 来阻断前列腺素合成。

Bromfenac Sodium is a nonsteroidal anti-inflammatory drug (NSAID) which has anti-inflammatory activity and may block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2.

Bromfenac (0-80 μg/mL; 24 h) can inhibit transforming growth factor-β2-induced epithelial-mesenchymal transition in HLEC-B3 in a concentration-dependent manner.Bromfenac (80 μg/Ml; 48 h) inhibits transforming growth factor-β2-induced epithelial-mesenchymal transition in human anterior capsules. Cell Viability Assay Cell Line:transforming growth factor-β2-treated human anterior capsules.Concentration:80 μg/mL Incubation Time:48 hours Result:Suppressed transforming growth factor-β2-induced epithelial-mesenchymal transition in primary lens epithelial cells (LECs).Cell Migration Assay Cell Line:HLEC-B3 cells Concentration:0, 20, 40, 60, and 80 μg/mL Incubation Time:24 hours Result:Suppressed transforming growth factor-β2-induced cell migration in HLEC-B3 cells, and exhibited inhibition of the over-expression of epithelial-mesenchymal transition markers.

Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18 h pretreatment time) in rats.Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats.Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs.Bromfenac (0.0032-0.1%; 50 μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats.Bromfenac (0.32%; 50 μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice.Bromfenac (eyedrop instillation; 1 μL (0.09%) per eye; twice-daily; 4 w) partially reduces corneal staining, and becomes so more slowly by the 4-week time point. Animal Model:Male Sprague-Dawley rats (150-250 g) are injected carrageenan Dosage:0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200 μL) Administration:Rubbed onto the backs before 1-72 h of injected carrageenan Result:Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%.Applied 1 or 4 h prior to carrageenan challenge was active, but not when applied 24 h (or longer) prior to challenge at 0.2%.

AHR 10282R | Bronuck | AHR 10282B

Chromatin/Epigenetic

COX

COX1 COX-2

Endocrinology

Ocular inflammation; Ocular pain

91714-93-1

356.15

C15H11BrNO3·Na

>98% (HPLC)

DMSO:66 mg/mL (185.3 mM);Ethanol:2 mg/mL (5.61 mM);Water:65 mg/mL (182.5 mM)

[Na+].NC1=C(C=CC=C1CC([O-])=O)C(=O)C1=CC=C(Br)C=C1

——

(-20℃)

With Ice Pack

≥ 2 years